A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.

Completed · Phase 3

Conditions studied: Glaucoma

In brief

To assess the effectiveness of latanoprost 0.005% ophthalmic solution dosed once-daily and timolol 0.5% dosed twice-daily in paediatric subjects of 18 years of age or under who are diagnosed with glaucoma.

Key facts

Study ID

NCT00716859

Run by

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

People needed

139

Starts

2008-07-01

Expected to finish

2009-11-01

Last updated by the study team

2021-02-03

Who can join

Age: 1 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female of 18 years of age or under
• Diagnosis of glaucoma
• IOP of 22 mmHg or above in at least 1 eye

You may not qualify if…

• Require surgery for acute angle closure
• Have had prior cyclodestructive procedures
• Have a history of ocular trauma or surgery in either eye within 3 months of the baseline visit

Where it is running

• Pfizer Investigational Site — Pembroke Pines, Florida, United States
• Pfizer Investigational Site — Atlanta, Georgia, United States
• Pfizer Investigational Site — Indianapolis, Indiana, United States
• Pfizer Investigational Site — Minneapolis, Minnesota, United States
• Pfizer Investigational Site — Henderson, Nevada, United States
• Pfizer Investigational Site — Henderson, Nevada, United States
• Pfizer Investigational Site — Las Vegas, Nevada, United States
• Pfizer Investigational Site — Leuven, Belgium
• Pfizer Investigational Site — Medellín, Antioquia, Colombia
• Pfizer Investigational Site — Bogota, Cundinamarca, Colombia
• Pfizer Investigational Site — Prague, Czechia
• Pfizer Investigational Site — Amiens, Cedex 1, France
• Pfizer Investigational Site — Lille, France
• Pfizer Investigational Site — Lyon, France
• Pfizer Investigational Site — Regenstauf, Germany
• Pfizer Investigational Site — Schorndorf, Germany
• Pfizer Investigational Site — Hyderabad, Andhra Pradesh, India
• Pfizer Investigational Site — Ahmedabad, Gujarat, India
• Pfizer Investigational Site — Coimbatore, Tamil Nadu, India
• Pfizer Investigational Site — Catania, Italy
• Pfizer Investigational Site — Milan, Italy
• Pfizer Investigational Site — Makati City, Philippines
• Pfizer Investigational Site — Mandaluyong, Philippines
• Pfizer Investigational Site — Bialystok, Poland
• Pfizer Investigational Site — Gdansk, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.